Jefferies Group Reaffirms Buy Rating for PetIQ (PETQ)

PetIQ (NASDAQ:PETQ)‘s stock had its “buy” rating reissued by equities research analysts at Jefferies Group in a research note issued to investors on Monday. They currently have a $27.00 target price on the stock. Jefferies Group’s price objective would indicate a potential upside of 21.79% from the stock’s current price.

The analysts wrote, “PETQ announced a $220M acquisition of VIP Petcare (~1.5x sales, >18x EBITDA), which is an operator of vet clinics within US retailers. The transaction materially expands PETQ’s TAM, diversifies its revenue base (now 75%/25% products/services), lowers its WMT exposure, and gives it greater leverage with suppliers/customers. Prelim. FY17 sales/EBITDA were in-line with expectations and FY19-20 targets call for 15%+/20%+ sales/EBITDA growth. Reit. Buy.””

Shares of PetIQ (PETQ) opened at $22.17 on Monday. PetIQ has a 52 week low of $17.03 and a 52 week high of $28.23. The company has a current ratio of 6.83, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19.

Hedge funds have recently added to or reduced their stakes in the company. Essex Investment Management Co. LLC acquired a new stake in shares of PetIQ in the 3rd quarter worth $2,162,000. Emerald Mutual Fund Advisers Trust acquired a new stake in shares of PetIQ in the 3rd quarter worth $1,856,000. Emerald Advisers Inc. PA acquired a new stake in shares of PetIQ in the 3rd quarter worth $2,498,000. EAM Investors LLC acquired a new stake in shares of PetIQ in the 3rd quarter worth $2,615,000. Finally, Eos Management L.P. acquired a new stake in shares of PetIQ in the 3rd quarter worth $143,836,000. Institutional investors own 56.49% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Reaffirms Buy Rating for PetIQ (PETQ)” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.themarketsdaily.com/2018/01/10/jefferies-group-reaffirms-buy-rating-for-petiq-petq.html.

PetIQ Company Profile

PetIQ, Inc is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield.

Analyst Recommendations for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply